Payment overview · 2025
General Payments
$207.43
4 reported records · 4 companies
Healthcare provider profile · identity verified
Anne Jones, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBUQUERQUE, NM · NPI 1003823048
Verified facts
What the public records show
CMS Open Payments records show Anne Jones, MD received $207.43 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 77.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $159.69 | 77.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.36 | 8.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.37 | 7.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.01 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.43 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $159.69 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 716 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 163 |
| Lisinopril | Lisinopril | 330 | 97 |
| Gabapentin | Gabapentin | 292 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 87 |
| Losartan Potassium | Losartan Potassium | 245 | 74 |
| Omeprazole | Omeprazole | 214 | 75 |
| Alendronate Sodium | Alendronate Sodium | 174 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 46 |
| Simvastatin | Simvastatin | 157 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 60 |
| Potassium Chloride | Potassium Chloride | 144 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 41 |
| Metformin Hcl | Metformin Hcl | 130 | 34 |
| Furosemide | Furosemide | 121 | 43 |
| Valsartan | Valsartan | 121 | 37 |
| Famotidine | Famotidine | 117 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 34 |
| Metformin Hcl Er | Metformin Hcl | 111 | 35 |
| Chlorthalidone | Chlorthalidone | 102 | 29 |
| Montelukast Sodium | Montelukast Sodium | 94 | 24 |
| Ezetimibe | Ezetimibe | 92 | 29 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 26 |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 23 |
| Donepezil Hcl | Donepezil Hcl | 70 | 17 |
| Xarelto | Rivaroxaban | 70 | 17 |
| Alprazolam | Alprazolam | 66 | 17 |
| Lovastatin | Lovastatin | 66 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 23 |
| Finasteride | Finasteride | 65 | 22 |
| Prednisone | Prednisone | 63 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | suppressed |
| Temazepam | Temazepam | 57 | suppressed |
| Eliquis | Apixaban | 56 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 18 |
| Allopurinol | Allopurinol | 54 | 17 |
| Carvedilol | Carvedilol | 54 | 17 |
| Meloxicam | Meloxicam | 54 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 52 | suppressed |
| Cephalexin | Cephalexin | 49 | 34 |
| Estradiol | Estradiol | 48 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 32 |
| Memantine Hcl | Memantine Hcl | 46 | 15 |
| Baclofen | Baclofen | 43 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Glipizide Er | Glipizide | 39 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 39 | 11 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Tramadol Hcl | Tramadol Hcl | 39 | 16 |
| Spironolactone | Spironolactone | 38 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Ibuprofen | Ibuprofen | 36 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 33 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 15 |
| Acyclovir | Acyclovir | 31 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Mupirocin | Mupirocin | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.43 · 4 records | Abbott Laboratories | FREESTYLE LIBRE 3, MOUNJARO, REXULTI, SHINGRIX, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error